^
Association details:
| Biomarker: | CMTR1-ALK fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
Excerpt:
NGS result revealed that this tumor specimen harbored a previously unknown CMTR1-ALK fusion variant....the patient dropped out of the crizotinib treatment and was treated with pemetrexed in November 2016, which delayed disease progression. The disease has remained under control for approximately 13 months at this time.
DOI:
10.1080/15384047.2018.1480282
